Olapag Tablet 50 mg contains Eltrombopag Olamine, a specialized oral medication designed to increase platelet production in individuals suffering from low platelet counts (thrombocytopenia). Eltrombopag is a thrombopoietin receptor agonist, which stimulates the bone marrow to produce more platelets, thereby reducing the risk of bleeding complications and improving overall blood health.

This higher-strength 50 mg formulation is suitable for patients requiring greater platelet support, such as those with chronic conditions like immune thrombocytopenia (ITP), chronic hepatitis C-associated thrombocytopenia, or severe aplastic anemia. Olapag 50 mg helps patients maintain safer platelet levels, allowing them to undergo essential medical procedures and therapies with reduced risk of bleeding.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Olapag Tablet 50 mg is indicated for:

• Chronic immune thrombocytopenia (ITP): To increase platelet counts in adults and children who do not respond adequately to standard therapy.

• HCV-associated thrombocytopenia: Facilitates initiation and continuation of antiviral therapy by elevating platelet levels.

• Severe aplastic anemia: Used with immunosuppressive therapy to improve platelet production in patients with low platelet counts.

• Other chronic thrombocytopenic conditions as directed by a healthcare professional.

Olapag should be used under the supervision of a hematologist or physician experienced in managing blood disorders.

Key Benefits

• Boosts platelet production: Helps prevent excessive bleeding and bruising in patients with thrombocytopenia.

• Supports safe medical procedures: Enables patients to undergo surgeries or therapies that require sufficient platelet levels.

• Convenient oral therapy: Tablet form ensures easy administration and consistent dosing.

• Enhances quality of life: Reduces the physical and psychological burden of chronic low platelet counts.

• Clinically proven efficacy: Eltrombopag is widely recognized for effectively managing platelet disorders.

Olapag Tablet 50 mg offers stronger platelet support for patients requiring higher therapeutic doses.

Dosage and Administration

• The usual starting dose is 50 mg once daily, taken orally, preferably on an empty stomach (at least 1 hour before or 2 hours after meals containing calcium, iron, magnesium, or aluminum).

• Dosage may be adjusted based on platelet counts, which should be regularly monitored.

• Take the tablet with a full glass of water; do not crush, chew, or split unless instructed by a physician.

• Adherence to the prescribed dose and schedule is critical for optimal outcomes.

Precautions

• Use with caution in patients with liver or kidney impairment; dose adjustments may be necessary.

• Monitor platelet levels regularly to prevent excessive platelet elevation, which could increase the risk of blood clots.

• Inform your doctor if you have a history of thromboembolic events, bleeding disorders, or other chronic conditions.

• Avoid supplements containing calcium, iron, magnesium, or aluminum within 2 hours of taking Olapag.

• Not recommended during pregnancy or breastfeeding unless specifically prescribed and monitored by a physician.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Olapag Tablet 50 mg is generally well tolerated. Common side effects include:

• Headache

• Nausea or vomiting

• Fatigue

• Abdominal discomfort or indigestion

• Muscle or joint pain

Rare but serious side effects may include liver function abnormalities, blood clots, or severe allergic reactions. Immediate medical attention is necessary if serious symptoms occur.

Storage Instructions

• Store below 25°C in a cool, dry place.

• Protect from moisture, light, and heat.

• Keep out of reach of children.

• Do not use after the expiration date printed on the packaging.

Olapag Tablet 50 mg (Eltrombopag Olamine) is a powerful and convenient oral therapy for managing thrombocytopenia. It effectively increases platelet counts, reduces bleeding risk, and supports patient safety and quality of life in chronic low platelet conditions.